Effect of proteinase inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy

T. Onbe, Hirofumi Makino, I. Kumagai, T. Haramoto, K. Murakami, Z. Ota

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The effect of serine protease inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy was evaluated. Eight patients with nephrotic syndrome associated with diabetic nephropathy were orally administered 600 mg of Camostat Mesilate per day. Three patients showed a reduction of urinary protein excretion promptly at 4 weeks. Serum protein and degree of edema improved significantly at 4 weeks. Camostat Mesilate had no effect on renal function assessed by creatinine clearance. During the observation period there were no significant changes in blood pressure, level of blood sugar, or HbA1c. Camostat Mesilate would be beneficial for the treatment of diabetic nephropathy.

Original languageEnglish
Pages (from-to)167-168
Number of pages2
JournalJournal of Diabetic Complications
Volume5
Issue number2-3
DOIs
Publication statusPublished - Jan 1 1991

Fingerprint

Nephrotic Syndrome
Diabetic Nephropathies
Peptide Hydrolases
Serine Proteinase Inhibitors
Blood Glucose
Blood Proteins
Edema
Creatinine
Observation
Blood Pressure
Kidney
camostat
Proteins
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Effect of proteinase inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy. / Onbe, T.; Makino, Hirofumi; Kumagai, I.; Haramoto, T.; Murakami, K.; Ota, Z.

In: Journal of Diabetic Complications, Vol. 5, No. 2-3, 01.01.1991, p. 167-168.

Research output: Contribution to journalArticle

Onbe, T. ; Makino, Hirofumi ; Kumagai, I. ; Haramoto, T. ; Murakami, K. ; Ota, Z. / Effect of proteinase inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy. In: Journal of Diabetic Complications. 1991 ; Vol. 5, No. 2-3. pp. 167-168.
@article{b013a32db6b648f29531e3290961ee8d,
title = "Effect of proteinase inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy",
abstract = "The effect of serine protease inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy was evaluated. Eight patients with nephrotic syndrome associated with diabetic nephropathy were orally administered 600 mg of Camostat Mesilate per day. Three patients showed a reduction of urinary protein excretion promptly at 4 weeks. Serum protein and degree of edema improved significantly at 4 weeks. Camostat Mesilate had no effect on renal function assessed by creatinine clearance. During the observation period there were no significant changes in blood pressure, level of blood sugar, or HbA1c. Camostat Mesilate would be beneficial for the treatment of diabetic nephropathy.",
author = "T. Onbe and Hirofumi Makino and I. Kumagai and T. Haramoto and K. Murakami and Z. Ota",
year = "1991",
month = "1",
day = "1",
doi = "10.1016/0891-6632(91)90060-3",
language = "English",
volume = "5",
pages = "167--168",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",
number = "2-3",

}

TY - JOUR

T1 - Effect of proteinase inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy

AU - Onbe, T.

AU - Makino, Hirofumi

AU - Kumagai, I.

AU - Haramoto, T.

AU - Murakami, K.

AU - Ota, Z.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - The effect of serine protease inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy was evaluated. Eight patients with nephrotic syndrome associated with diabetic nephropathy were orally administered 600 mg of Camostat Mesilate per day. Three patients showed a reduction of urinary protein excretion promptly at 4 weeks. Serum protein and degree of edema improved significantly at 4 weeks. Camostat Mesilate had no effect on renal function assessed by creatinine clearance. During the observation period there were no significant changes in blood pressure, level of blood sugar, or HbA1c. Camostat Mesilate would be beneficial for the treatment of diabetic nephropathy.

AB - The effect of serine protease inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy was evaluated. Eight patients with nephrotic syndrome associated with diabetic nephropathy were orally administered 600 mg of Camostat Mesilate per day. Three patients showed a reduction of urinary protein excretion promptly at 4 weeks. Serum protein and degree of edema improved significantly at 4 weeks. Camostat Mesilate had no effect on renal function assessed by creatinine clearance. During the observation period there were no significant changes in blood pressure, level of blood sugar, or HbA1c. Camostat Mesilate would be beneficial for the treatment of diabetic nephropathy.

UR - http://www.scopus.com/inward/record.url?scp=0025950228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025950228&partnerID=8YFLogxK

U2 - 10.1016/0891-6632(91)90060-3

DO - 10.1016/0891-6632(91)90060-3

M3 - Article

VL - 5

SP - 167

EP - 168

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 2-3

ER -